Editorial & Opinion
أعرض في EDS

Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer.

التفاصيل البيبلوغرافية
العنوان: Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer.
المؤلفون: Pope B; Department of Surgery, The University of Melbourne, 5th Floor Clinical Sciences Building, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia; Melbourne Bioinformatics, The University of Melbourne, Carlton, Australia; Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia; Department of Clinical Pathology, The University of Melbourne, Victorian Comprehensive Cancer Centre, Melbourne, Australia. Electronic address: bjpope@unimelb.edu.au., Park G; Early Cancer Institute, University of Cambridge Department of Oncology, Hutchison Research Centre, Cambridge, UK; Cancer Research UK Cambridge Centre, Cambridge, UK; Department of Oncology, University of Cambridge Hutchison-MRC Research Centre, Cambridge, UK., Lau E; Department of Surgery, The University of Melbourne, 5th Floor Clinical Sciences Building, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia; Melbourne Bioinformatics, The University of Melbourne, Carlton, Australia., Belic J; Early Cancer Institute, University of Cambridge Department of Oncology, Hutchison Research Centre, Cambridge, UK; Cancer Research UK Cambridge Centre, Cambridge, UK; Department of Oncology, University of Cambridge Hutchison-MRC Research Centre, Cambridge, UK., Lach R; Early Cancer Institute, University of Cambridge Department of Oncology, Hutchison Research Centre, Cambridge, UK; Cancer Research UK Cambridge Centre, Cambridge, UK; Department of Oncology, University of Cambridge Hutchison-MRC Research Centre, Cambridge, UK., George A; Department of Oncology, University of Cambridge Hutchison-MRC Research Centre, Cambridge, UK; Department of Surgery, Division of Urology, University of Cambridge, Cambridge, UK; Department of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Academic Urology Group, Department of Surgery, University of Cambridge, Cambridge, UK; Cambridge Urology Translational Research and Clinical Trials, Cambridge, UK., McCoy P; Department of Surgery, The University of Melbourne, 5th Floor Clinical Sciences Building, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia., Nguyen A; Department of Surgery, The University of Melbourne, 5th Floor Clinical Sciences Building, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia., Grima C; Department of Surgery, The University of Melbourne, 5th Floor Clinical Sciences Building, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia., Campbell B; Department of Surgery, The University of Melbourne, 5th Floor Clinical Sciences Building, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia., Jung CH; Melbourne Bioinformatics, The University of Melbourne, Carlton, Australia., Ditter EJ; Cancer Research UK Cambridge Centre, Cambridge, UK; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Zhao H; Cancer Research UK Cambridge Centre, Cambridge, UK; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Wedge DC; Manchester Cancer Research Centre, University of Manchester, Manchester, UK., Brewer DS; Norwich Medical School, University of East Anglia, Norwich, UK; Earlham Institute, Norwich, UK., Lynch AG; School of Medicine, University of St. Andrews, St. Andrews, UK; School of Mathematics and Statistics, University of St. Andrews, St. Andrews, UK., Dev H; Early Cancer Institute, University of Cambridge Department of Oncology, Hutchison Research Centre, Cambridge, UK; Cancer Research UK Cambridge Centre, Cambridge, UK; Department of Oncology, University of Cambridge Hutchison-MRC Research Centre, Cambridge, UK., Gnanpragasam VJ; Department of Surgery, Division of Urology, University of Cambridge, Cambridge, UK; Department of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Cambridge Urology Translational Research and Clinical Trials, Cambridge, UK., Rosenfeld N; Cancer Research UK Cambridge Centre, Cambridge, UK; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Hovens CM; Department of Surgery, The University of Melbourne, 5th Floor Clinical Sciences Building, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia; Department of Urology, Western Health, Footscray, Australia; Australian Prostate Cancer Research Centre, Melbourne, Australia., Corcoran NM; Department of Surgery, The University of Melbourne, 5th Floor Clinical Sciences Building, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia; Department of Urology, Western Health, Footscray, Australia; Department of Urology, Royal Melbourne Hospital, Parkville, Australia; Victorian Comprehensive Cancer Centre, Parkville, Australia., Massie CE; Early Cancer Institute, University of Cambridge Department of Oncology, Hutchison Research Centre, Cambridge, UK; Cancer Research UK Cambridge Centre, Cambridge, UK; Department of Oncology, University of Cambridge Hutchison-MRC Research Centre, Cambridge, UK.
مؤلفون مشاركون: Pan Prostate Cancer Group (PPCG); The Institute of Cancer Research, London, UK.
المصدر: European urology [Eur Urol] 2024 Apr; Vol. 85 (4), pp. 407-410. Date of Electronic Publication: 2024 Feb 19.
نوع المنشور: Letter
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Country of Publication: Switzerland NLM ID: 7512719 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7560 (Electronic) Linking ISSN: 03022838 NLM ISO Abbreviation: Eur Urol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2002- : Amsterdam : Elsevier Science
Original Publication: Basel, New York, Karger.
مواضيع طبية MeSH: Circulating Tumor DNA*/genetics , Prostatic Neoplasms*/pathology, Male ; Humans ; Prostate-Specific Antigen ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/diagnosis ; Prostatectomy
معلومات مُعتمدة: 28292 United Kingdom CRUK_ Cancer Research UK
المشرفين على المادة: 0 (Circulating Tumor DNA)
EC 3.4.21.77 (Prostate-Specific Antigen)
تواريخ الأحداث: Date Created: 20240220 Date Completed: 20240318 Latest Revision: 20240320
رمز التحديث: 20240320
DOI: 10.1016/j.eururo.2024.01.002
PMID: 38378299
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-7560
DOI:10.1016/j.eururo.2024.01.002